These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA. Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study. Yen CY; Yen JC; Chen CC; Hu HY; Cheng FS; Tseng PC Medicine (Baltimore); 2022 Aug; 101(33):e30115. PubMed ID: 35984152 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA; JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939 [TBL] [Abstract][Full Text] [Related]
7. Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab. Wood EH; Karth PA; Moshfeghi DM; Leng T Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):950-4. PubMed ID: 26469235 [TBL] [Abstract][Full Text] [Related]
8. Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients. Ruiz-Moreno JM; de Andrés-Nogales F; Oyagüez I BMC Ophthalmol; 2020 Sep; 20(1):371. PubMed ID: 32943041 [TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415 [TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007419. PubMed ID: 30325017 [TBL] [Abstract][Full Text] [Related]
11. Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection. Nawar AE; Wasfy T; Shafik HM BMC Ophthalmol; 2022 Jun; 22(1):287. PubMed ID: 35768859 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR; JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850 [TBL] [Abstract][Full Text] [Related]
13. Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. Kiss S; Malangone-Monaco E; Wilson K; Varker H; Stetsovsky D; Smith D; Garmo V J Manag Care Spec Pharm; 2020 Mar; 26(3):253-266. PubMed ID: 32020843 [TBL] [Abstract][Full Text] [Related]
14. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Glassman AR; Wells JA; Josic K; Maguire MG; Antoszyk AN; Baker C; Beaulieu WT; Elman MJ; Jampol LM; Sun JK Ophthalmology; 2020 Sep; 127(9):1201-1210. PubMed ID: 32402554 [TBL] [Abstract][Full Text] [Related]
15. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA; JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288 [TBL] [Abstract][Full Text] [Related]
16. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA; JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655 [TBL] [Abstract][Full Text] [Related]
17. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709 [TBL] [Abstract][Full Text] [Related]
18. [The effect of intravitreally administered angiogenesis inhibitor on the concentration of angiotensin-converting enzyme in the blood serum and lacrimal fluid in patients with diabetic macular edema]. Neroev VV; Chesnokova NB; Okhotsimskaya TD; Ryabina MV; Fadeeva VA; Pavlenko TА; Beznos OV Probl Endokrinol (Mosk); 2019 Jun; 65(2):72-78. PubMed ID: 31271708 [TBL] [Abstract][Full Text] [Related]
19. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial. Jampol LM; Glassman AR; Bressler NM; Wells JA; Ayala AR; JAMA Ophthalmol; 2016 Dec; 134(12):. PubMed ID: 27711918 [TBL] [Abstract][Full Text] [Related]